July 27, 2014 | Atox Bio, an Israeli company developing therapeutics for serious infections, announced that it raised $23 million in an investment round led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel. The funds will be used by Atox Bio to begin late stage clinical trials of AB1o3, a therapy treatment for Necrotizing Soft Tissue Infections or “flesh-eating bacteria,” as well as other serious infections. The AB103 immunomodulator was discovered by Prof. Raymond Kaempfer and Dr. Gila Arad.
Related posts
Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023
Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023
Israel Opens Its First Satellite Observatory
February 02, 2023
Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments